ACRS Aclaris Therapeutics Inc. Total Asset Value of Company
This chart of Aclaris Therapeutics (ACRS) share prices highlights logistical stability driven by partnerships with various global laboratories, with total assets amounting to 184.42. The company's growth relies on the success of kinase inhibitor tests and the potential for acquisition by industry behemoths. The business generates revenue through exclusive dermatology patents, which provide the pricing power to set high costs for systemic pathology therapies.
Analytical breakdowns and data insights for company Aclaris (ACRS)
- current quotes and average value forecast:
- market capitalization data:
- issuer book value statistics:
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Aclaris Therapeutics|ACRS - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Aclaris Therapeutics, Inc|ACRS - Company Aggregate Debts|Debts to Book Capitalization Aclaris Therapeutics, Inc|ACRS - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Aclaris Therapeutics|Interim Coverage Ratio aclaristx.com
- net income and valuation multiples indicators:
Fundamental valuation:Aclaris Therapeutics
For an investor in Aclaris Therapeutics (ACRS), this metric serves as a gauge of the resource base required for the development of immunological drugs. The company's financial asset volume is calculated inversely via ROA, consolidating equity and liabilities into a single cash equivalent. This resource trend reflects the business's ability to sustain R&D until product commercialization. In the future, the patent uniqueness of the molecules will transform current capital into high market value.
Key competitors
ARGX - Company Total Asset Base|Aggregate Company Assets BioNTech|Abivax - Total Asset Value of Company|Company Total Assets ADMA|PTGX (Protagonist Corp) - Aggregate Asset Value|Company Total Assets IMVT (Immunovant, Inc.)|Company Total Assets kiniksa.com KNSA|GRFS - Aggregate Company Assets|Aggregate Asset Value ADPT (Adaptive Biotech)|Celldex (CLDX) - Aggregate Company Assets|Cumulative Company Assets Aurinia Corp|BCRX (BioCryst) - Company Total Assets|Company Total Assets veratx.com|Cumulative Company Assets DNTH (Dianthus Therapeutics, Inc.)|PHVS (Pharvaris NV) - Aggregate Asset Value|Company Total Assets ABCL (abcellera.com)|Company Total Asset Base Tourmaline (TRML)|PGEN - Aggregate Company Assets|pharming.com (PHAR) - Cumulative Company Assets|Nektar Therapeutics Inc. (NKTR) - Aggregate Company Assets|Cumulative Company Assets Upstream Bio, Inc.|Cumulative Company Assets ZBIO|Company Total Assets Immunome Bio|Aggregate Company Assets Gossamer Bio, Inc. (GOSS)|kalvista.com - Total Business Assets|Company Total Assets SEPN (Septerna)|Pieris Pharma (PVLA) - Company Assets|Savara Corp - Company Total Assets|RIGL - Company Total Assets|ANAB: Company Total Assets|Cumulative Company Assets astriatx.com|Aggregate Company Assets enGene|Aggregate Company Assets RAPT|Company Total Assets JBIO|Company Total Assets Kyverna Therapeutics, Inc (KYTX)|Aggregate Company Assets Tiziana Life Sciences TLSA|Aggregate Asset Value CABA|Ventyx Biosciences, Inc. - Company Total Assets|Company Total Asset Base Theratechnologies, Inc. THTX|Avalo Therapeutics Inc. (AVTX) - Aggregate Company Assets|ELDN - Company Total Asset Base|Cumulative Company Assets AGEN|CLYM: Aggregate Asset Value|Cumulative Company Assets ZURA (Zura Bio)|Aggregate Business Assets ATYR|Company Total Assets ADAG (Adagene Inc.)|Aggregate Asset Value IMA|Shattuck Therapeutics - Company Total Assets|Company Assets Equillium, Inc.|connectbiopharm.com (CNTB) - Aggregate Company Assets|Immunic - Aggregate Asset Value|ATRA (Atara Biotherapeutics, Inc.) - Company Total Assets|Company Total Assets InflaRx GmbH|Aggregate Company Assets X4 Pharmaceuticals (XFOR)|ACET: Total Asset Value of Company|Company Total Assets CELU (Celularity)|INmune Bio Inc (INMB) - Company Assets|BRNS: Cumulative Company Assets|KZR - Company Total Assets|SABS (SAB Biotherapeutics) - Cumulative Company Assets|AKTX: Aggregate Business Assets|ENLV (Enlivex Therapeutics Ltd) - Company Total Assets|Q32 Bio Corp (QTTB) - Company Total Asset Base|Company Total Assets GOVX|Cumulative Company Assets Edesa Biotech Corp EDSA|Aggregate Company Assets iBio, Inc. IBIO|Company Total Asset Base Carisma Therapeutics Inc (CARM)|XTL Biopharmaceuticals Ltd. - Company Total Assets|BOLT - Company Total Assets|HCWB: Company Total Assets|Cumulative Company Assets Aptevo Therapeutics Inc.|Aggregate Company Assets AIM ImmunoTech Inc.|ADTX: Aggregate Asset Value|Aggregate Company Assets GRI Bio (GRI)|Company Total Asset Base XORTX Therapeutics Inc|Aggregate Company Assets ReShape Lifesciences HIND|REVB (Revelation Biosciences Corp) - Total Asset Value of Company|Indaptus Therapeutics - Company Total Assets|Aggregate Asset Value SCNI (scinai.com)|CALI: Company Total Assets|Affimed N.V. (AFMD) - Company Total Assets|Aggregate Company Assets Allakos Inc|HOOK: Aggregate Asset Value|Aggregate Company Assets IGM Biosciences, Inc. (IGMS)|Cumulative Company Assets iteostherapeutics.com ITOS|Company Total Assets OCEA (Ocean Biomedical)|Company Total Assets TC BioPharm (Holdings) Plc TCBP|THRD: Cumulative Company Assets